5,302 Shares in Zoetis Inc. (NYSE:ZTS) Bought by One Wealth Capital Management LLC

One Wealth Capital Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,302 shares of the company’s stock, valued at approximately $864,000.

A number of other large investors also recently bought and sold shares of ZTS. Canandaigua National Bank & Trust Co. lifted its position in Zoetis by 27.9% in the fourth quarter. Canandaigua National Bank & Trust Co. now owns 7,236 shares of the company’s stock valued at $1,179,000 after purchasing an additional 1,580 shares during the period. CWA Asset Management Group LLC lifted its holdings in shares of Zoetis by 118.9% in the 4th quarter. CWA Asset Management Group LLC now owns 16,028 shares of the company’s stock valued at $2,611,000 after buying an additional 8,706 shares during the period. Pensionfund Sabic boosted its stake in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares during the period. Finally, GAMMA Investing LLC increased its stake in Zoetis by 36.4% in the 4th quarter. GAMMA Investing LLC now owns 11,862 shares of the company’s stock valued at $1,933,000 after purchasing an additional 3,165 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.6 %

NYSE ZTS traded down $2.60 during trading hours on Tuesday, hitting $163.30. The company had a trading volume of 1,826,928 shares, compared to its average volume of 2,198,894. The firm’s 50 day moving average is $173.07 and its 200 day moving average is $180.47. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a market capitalization of $73.68 billion, a price-to-earnings ratio of 30.70, a P/E/G ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.36 earnings per share. Sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. Zoetis’s dividend payout ratio is 37.59%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ZTS shares. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.